Introduction
============

Ménière's disease is an illness in which multi-modal treatment is the norm. Lifestyle changes, physical therapy, vestibular adaptation, drug therapy, and ablative and non-ablative surgery are all options in its treatment and are frequently used in combination. Among all of the drug therapies used, betahistine (Serc^®^, BetaSerc^®^; Solvay Pharmaceuticals) is the most frequently chosen in Europe; in a recent survey, 94% of physicians in the UK prescribe betahistine for Ménière's disease ([@b83-ndt-3-429]) and the drug has been employed in the treatment of Ménière's disease and vertigo of peripheral vestibular origin for more than 40 years. However, until recently, the efficacy of this drug had not been evaluated to modern standards and its mechanism of action remained obscure. The objective of this review is to evaluate the evidence for the efficacy of betahistine in Ménière's disease and examine the latest evidence on its mechanism of action.

Ménière's disease
=================

Definition
----------

Ménière's disease comprises recurrent spontaneous episodes of rotatory vertigo spells that patients describe as a spinning or whirling feeling and sensorineural hearing loss (SNHL) accompanied by recruitment and tinnitus. An unpleasant sensation of aural fullness on the affected side may also occur ([@b96-ndt-3-429]). Ménière's disease is also called idiopathic endolymphatic hydrops (ELH), a term which describes a disorder of the inner ear in which there is a build-up of endolymph ([@b2-ndt-3-429]). Of the various symptoms of Ménière's disease, vertigo is usually the most troublesome, at least in the acute phase, due to its unpredictable nature ([@b22-ndt-3-429]; [@b47-ndt-3-429]). Vertigo spells can last from several minutes to several days and are frequently debilitating. Anxiety, depression, and space and motion disorder (an inability to orientate oneself and the difficulties encountered in large spaces or by moving surroundings) often develop ([@b6-ndt-3-429]). During vertigo attacks, patients are quite unable to undertake normal work or social activities. Nausea is common and patients may vomit during an attack. Sleepiness may follow for several hours, and an off-balance sensation may last for a number of days. Quality of life is frequently seriously diminished ([@b22-ndt-3-429]). During later stages of the disease, hearing loss, sound distortion, recruitment, and tinnitus further affect quality of life ([@b50-ndt-3-429]).

Epidemiology
------------

Together with back pain and headaches, dizziness and vertigo are among the most common symptoms causing patients to visit their physician. For example, a community survey among 50- to 60-year-olds revealed that a quarter currently suffered from giddiness or dizziness ([@b85-ndt-3-429], [@b86-ndt-3-429]). Such problems tend to become more common and more severe with age, so that by age 80 years, up to two-thirds of women and one third of men will have experienced episodes of vertigo. ([@b62-ndt-3-429]). Ménière's disease is a common cause of dizziness and vertigo spells. In most cases only one ear is involved, but both ears may be affected in about one third of patients. If both ears are affected, the disease generally starts in the second ear within the five first years of onset of the first ear. Ménière's disease typically starts between the ages of 20 and 50 years, a diagnosis rate that increases with age up to 60 years (Wladislavosky et al 1980). Men and women are equally affected.

There is considerable disagreement in the world literature about the incidence and prevalence of Ménière's disease with estimates varying by as much as a factor of 10 from country to country. Ranges of prevalence vary from over 200 cases/100,000 in the USA (with an incidence of over 15 cases/100,000 persons/year) ([@b24-ndt-3-429]) to prevalences as low as fewer than 20/100,000 in Japan (Wanatabe et al 1995; [@b81-ndt-3-429]), with a prevalence level of about 46/100,000 in Scandinavia ([@b84-ndt-3-429]; [@b53-ndt-3-429]), making Ménière's disease four times more common than otosclerosis. Although vertigo symptoms may decline with time leading to a "burn-out" of the inner ear, [@b42-ndt-3-429] have shown a progression of the intensity of the vertigo symptoms during the longitudinal course of Ménière's disease. In a prospective study of 243 consecutive patients admitted to their hospital, they found that the proportion of patients reporting severe or very severe attacks increased with the duration of symptoms. Nausea was also more common later in the disease than at the beginning. Sudden falls due to otolythic crisis ([@b95-ndt-3-429]) may arise many years after the last vertigo spell. Up to 25% of patients with Ménière's disease may eventually require a surgical procedure to control the vertigo attacks ([@b35-ndt-3-429]). Overall this suggests that untreated Ménière's disease worsens over time.

Pathophysiology
---------------

Although the underlying cause of Ménière's disease remains obscure and ELH is one of the common final physiopathological responses of the inner ear to many factors ([@b48-ndt-3-429]), Ménière's disease nevertheless results from an abnormality in the fluid homeostasis of the inner ear ([@b7-ndt-3-429]). The proposed two phase model in which there is an imbalance between endolymph production and resorption ([@b31-ndt-3-429], [@b32-ndt-3-429]) leading to volume expansion without pressure increase ([@b102-ndt-3-429]), is complemented with round membrane characteristics ([@b34-ndt-3-429]), perilymphatic regulating mechanisms ([@b57-ndt-3-429]), and aquaporin involvement.

With the increase of ELH, there is a risk of a rupture in the membranous labyrinth, with the consequent mixing of endolymph and perilymph. The changing levels of potassium are presumed to give rise to the vestibular symptoms. The rupture of the membrane with hydrops is thought to explain the amelioration of the cochlear symptoms when vertigo appears. The repetition of hydrops crises and repeated rupture of the membrane are thought, in turn, to be responsible for the progressive destruction of the labyrinth and give rise to the evolution of profound deafness and disappearance of vertigo. Although the evidence for ELH as the pathophysiological basis of Ménière's disease is well supported by scientific evidence, there is also evidence to suggest that it is not the only mechanism ([@b66-ndt-3-429]). For instance ganglionitis has been reported to contribute to Ménière's disease (Selamani et al 2005).

Therapeutic management
----------------------

### Acute treatment

The first goal in the acute phase is to symptomatically control the vertigo spells by stopping the rotational sensation and accompanying nausea and neurovegetative symptoms. Drug treatment with anti-emetics (eg, domperidone), vestibulosedative anti-histamines (eg, meclizine), and central sedative drugs with vestibulo-suppressive or anti-emetic effect (eg, diazepam, sulpiride, dihydrobenzperidol, and phenothiazine) are useful during this phase of treatment. Nausea and vomiting frequently require that such drugs are given by intra-rectal or parenteral routes. Although widely used, there is little evidence to guide the physician in choosing one of these medications over another for a particular patient.

### Long-term treatment

Long-term treatment has as its goal to prevent or diminish further spells of vertigo, to assist the patient with compensation for the vestibular deficit, to ameliorate or assist with the hearing loss and associated symptoms. Treatment modalities will include counselling, life style adaptation, drug therapy, rehabilitation, and surgery according to the stage and progression of the illness.

Because of the uncertainties of the illness, counseling is required for all patients. General life style adaptations consist of salt restriction and avoidance of caffeine, alcohol, tobacco, and coping with stress. Patients can frequently identify an event that provokes attacks and can be counseled to avoid such situations.

### Chronic drug therapy

Drug therapy can play an important role in the treatment of most Ménière's disease patients (for overview: [@b19-ndt-3-429], [@b20-ndt-3-429]). Betahistine is of benefit and, unlike sedative alternatives, does not interfere with the development of vestibular compensation. Diuretics can also be of benefit ([@b51-ndt-3-429]; [@b97-ndt-3-429]), although the use of acetazolamide in Ménière's disease is still controversial. When the transition from acute to chronic treatment fails to alleviate symptoms, mild vestibular sedatives such as cinnarizine may be of help.

Where an inflammatory component is suspected in bilateral Ménière's disease, short courses of systemic glucocorticoids may be appropriate. It recently has been shown that glucocorticoids not only influence inflammatory process in Ménière's disease, but also alter fluid dynamics via an interaction with the sodium pumps in the semicircular canals (Ponduglula et al 2004). Intra-tympanic application of corticosteroids appears to have only temporary effects ([@b28-ndt-3-429]) and is probably not recommended ([@b30-ndt-3-429]).

Anti-depressive treatment (eg, selective serotonin reuptake inhibitors) may improve the psychological handicap aspect of vertigo in pre-existing depression, but is of no benefit to vertigo itself nor in patients without pre-existing depression ([@b44-ndt-3-429]). Where anxiety and stress susceptibility exacerbate the condition, short courses of benzodiazepines (eg, alprazolam or serenase) can be administered, but dependence is a concern during the longer term.

### Vestibular rehabilitation

Vestibular rehabilitative therapy is useful for central vestibular compensation of peripheral vestibular asymmetry and consequent motion intolerance. Evidence is accumulating that Ménière's disease patients can benefit from this therapy with a general or customized training program ([@b21-ndt-3-429]; Dowdol-Ostorn 2002). When choosing drug therapy it is important to consider its effect on vestibular compensation; sedative drugs can seriously impair the process and are to be avoided if at all possible.

Betahistine
===========

Mechanism of action
-------------------

Histamine (HA) is a neuromodulatory transmitter that regulates various cerebral functions (wakefulness: [@b60-ndt-3-429]; cardio-vascular regulation: [@b59-ndt-3-429], [@b58-ndt-3-429]). In mammals, the histaminergic neurons are exclusively located in the tuberomammillary (TM) nuclei of the posterior hypothalamus ([@b73-ndt-3-429]) but the histaminergic nerve endings show a wide distribution throughout the whole brain. Three types of HA receptors have been identified: the postsynaptic histamine H1 and H2 receptors ([@b77-ndt-3-429]) and the presynaptic histamine H3 receptors ([@b10-ndt-3-429]; [@b78-ndt-3-429]). HA and histamine H3 receptor agonists inhibit HA turnover while HA receptor antagonists increase HA turnover and release in the central nervous system (CNS). The HA-containing perikarya of the TM nuclei send axonal projections to the whole vestibular nuclei (VN) complex in many species ([@b3-ndt-3-429]: guinea pig; [@b71-ndt-3-429]: rat; [@b88-ndt-3-429]: cat). In addition, all three categories of HA receptors are present in the VN and reciprocal connections between the VN and the TM nuclei are supported by electrophysiological ([@b43-ndt-3-429]), immunohistochemical ([@b93-ndt-3-429]), molecular ([@b40-ndt-3-429], [@b39-ndt-3-429]), and behavioral ([@b87-ndt-3-429]) investigations. Taken together, the data strongly suggest that HA regulates also the vestibular functions (see [@b55-ndt-3-429] for a review). Indeed, HA modulation of second-order vestibular neurons was found both in vitro ([@b46-ndt-3-429]) and in vivo ([@b72-ndt-3-429]; [@b45-ndt-3-429]; [@b80-ndt-3-429]) preparations. Moreover, chronic infusion of HA receptor ligands in the VN on one side induces behavioral modifications ([@b105-ndt-3-429]). Postural and oculomotor deficits similar to those seen after a unilateral vestibular loss were found following H2 receptor antagonists or H3 receptor agonists perfusion whereas the vestibular syndrome was reversed after local administration of H2 receptor agonists or H3 receptor antagonists.

Betahistine in vestibular disorders
-----------------------------------

Betahistine dihydrochloride is one of the drugs currently prescribed in patients with vestibular loss for their symptomatic treatment of vertigo, and especially in Ménière's patients ([@b75-ndt-3-429]). It is a structural analog of HA with weak histamine H1 receptor agonist and more potent histamine H3 receptor antagonist properties ([@b8-ndt-3-429]; [@b94-ndt-3-429]). Some sites of action of betahistine are known since a long time while new basic mechanisms at the CNS level were elucidated in a recent past only (see [@b55-ndt-3-429]).

### Peripheral mechanisms

Until recently, it was generally believed that the efficacy of betahistine was due to vascular mechanisms in the inner ear. Increase in cochlear blood flow was reported after systemic administration of betahistine ([@b67-ndt-3-429]; [@b59-ndt-3-429], [@b58-ndt-3-429]). The authors found that betahistine antagonizes the H3 heteroreceptors of the cochleo-vestibular vascular tree through the activation of autonomic alpha-2 receptors. Vasodilatation of the anterior inferior cerebellar artery could be involved, suggesting that the betahistine-induced increase in cochlear blood flow was associated with an increase in vascular conductivity and a decrease in systemic blood pressure. This effect appears to involve histamine H1 receptors, histamine presynaptic H3 heteroreceptors, and autonomic alpha-2 receptors, at least in the guinea pig inner ear.

Another peripheral mechanism was recently put forward by [@b15-ndt-3-429] in the frog. The authors examined the effects of betahistine on isolated preparations of frog posterior semicircular canals and found a decrease of the resting discharge of the ampullar receptors when the drug was administrated via the perilymphatic fluid. The effect could involve HA receptors in the peripheral vestibular system, a mechanism that remains, however, to be confirmed. More recently, H3 antagonists such as thioperamide and betahistine were found to decrease the electrical discharge of afferents neurons in the axolotl by interfering with the postsynaptic response to excitatory amino acid agonists ([@b17-ndt-3-429]). The results support the idea that antivertigo action of HA-released drugs may be caused, at least in part, by a decrease in the sensory input from the vestibular endorgans.

Whatever the real nature of the mechanism elicitated at the peripheral level after administration of betahistine, it seems that it contributes, at least partly, to the antivertigo property of the drug.

### Central mechanisms

There is today a growing body of data indicating that HA acts also on central neuronal networks involved in the recovery process after vestibular loss ([@b55-ndt-3-429]), and that betahistine-induced improvements in vestibular disorders and vertigo result from such central effects at various CNS levels.

It has clearly been shown that the behavioral recovery process after unilateral vestibular neurectomy (UVN) in the cat is strongly accelerated under betahistine treatment ([@b90-ndt-3-429]). Betahistine treatment reduces the time to recovery by 2 weeks for both static (posture) and kinetic (locomotor equilibrium) functions compared with controls (untreated and double blind, placebo-controlled animals ([Figure 1](#f1-ndt-3-429){ref-type="fig"}). Immunohistochemical investigations performed in the same cat model suggest that improvement in vestibular compensation is related to changes in HA synthesis and release ([@b89-ndt-3-429]). Further studies using an in situ hybridization method for quantifying the messenger RNA for histidine decarboxylase (HDC), the enzyme synthesizing HA, pointed to an up-regulation of HDC mRNA in the TM nuclei of cats treated with HA-like drugs ([@b92-ndt-3-429]) ([Figure 2](#f2-ndt-3-429){ref-type="fig"}). In addition, receptor binding studies showed a downregulation of histamine H3 receptors in both the VN and TM nuclei. It seems very likely, therefore, that betahistine upregulates HA turnover by blocking the presynaptic histamine H3 receptors. This hypothesis is corroborated by the well known role of these receptors in mediating autoinhibition of brain HA release ([@b10-ndt-3-429]) and autoregulation of HA synthesis ([@b9-ndt-3-429], [@b11-ndt-3-429]). In rat brain slices, agonists and antagonists of the histamine H3 receptors reduce and enhance HA release, respectively ([@b10-ndt-3-429], [@b9-ndt-3-429]; [@b38-ndt-3-429]).

The VN are known to play a crucial role in the recovery process after vestibular lesion ([@b56-ndt-3-429]; [@b82-ndt-3-429]) and are involved in an histaminergic vestibulo-hypothalamo-vestibular loop. It has been demonstrated recently that this histaminergic loop was implicated in the adaptive response to vestibular lesion ([@b93-ndt-3-429]). HDC mRNA expression was: up-regulated in the ipsilateral TM nucleus in UVN cats; up-regulated in the contralateral TM nucleus in compensated UVN cats submitted to a second vestibular nerve section on their intact side (two steps bilateral vestibular neurectomy); and unchanged in one step bilateral vestibular neurectomized cats. The effectiveness of betahistine in the treatment of vertigo and vestibular disease can be seen therefore by the effects of HA release on second-order vestibular neurons. HA depolarizes the medial VN cells in vitro in rats ([@b72-ndt-3-429]; [@b45-ndt-3-429]) and guinea pigs ([@b80-ndt-3-429]; [@b100-ndt-3-429]). The VN control the vestibulo-ocular and vestibulo-spinal reflexes ([@b101-ndt-3-429]; [@b54-ndt-3-429]) and plays a major role in gaze stabilization, a function that is strongly impaired after vestibular loss and alteration of the peripheral vestibular system.

Antihistamines have been found effective in vertigo treatment probably due to central depressive effects. HA ([@b36-ndt-3-429]) and HA-like drugs such as betahistine dihydrochloride have been used also as antivertigo agents for over 20 years (see [@b75-ndt-3-429] for a review). A major advantage of betahistine is that no sedative effects were observed following its administration in animal models ([@b60-ndt-3-429]) or in healthy subjects ([@b12-ndt-3-429]). On the contrary, HA-induced excitatory effects on the neuronal activity of cortical and subcortical structures in the cat by activating histamine H1 receptors ([@b60-ndt-3-429]). These other central targets of HA very likely participate to the restoration of vestibular functions, indirectly. Indeed, brain arousal facilitates sensorimotor activity, a factor that was found crucial for the recovery process after vestibular loss in the cat ([@b104-ndt-3-429]; [@b56-ndt-3-429]).

Finally, a dose-dependent and duration-dependent effect of betahistine treatment on HA turnover in the cat has been reported ([@b91-ndt-3-429]). With a low dose (2 mg/kg) given over a long time period (3 months), similar to the dosing used clinically and reported to have anti-vertigo effects ([@b70-ndt-3-429]; [@b23-ndt-3-429]; [@b49-ndt-3-429]), HA synthesis and release were significantly increased in our animal model. The data are in favor of symptomatic treatment of vertigo in humans by means of HA-like drugs.

Clinical efficacy
-----------------

Over the years, betahistine has acquired a dominant position in the pharmacotherapeutic armamentarium for Ménière's disease and other disorders of the inner ear. It is associated with the beneficial effects of histamine, but, unlike histamine, is does not cause headaches, flushing, blurred vision, vomiting, or sedation. Thus patients whose Ménière's disease is controlled by betahistine can maintain their lifestyles without fear of fall and fractures, and, most importantly betahistine does not interfere with vestibular rehabilitation.

Betahistine has been widely used for management of a range of disorders including Ménière's disease vertigo of various origin and tinnitus, with good results and widespread acceptance by physicians for many years. However, until relatively recently this widespread use was not based fully supported by modern standards of evidence based medicine. However, in recent years a number of high-quality studies have been completed which better confirm the efficacy of betahistine in Ménière's disease. The time is therefore opportune to review the evidence base for betahistine.

Clinical studies on betahistine up to the year 2000 have been reviewed by [@b64-ndt-3-429]. In this period there were more than 20 controlled clinical studies of betahistine and, while none could be considered methodologically flawless, taken together they strongly suggest that betahistine is effective in reducing the frequency, severity and duration of vertigo and possibly neurovegitative symptoms in vertigo of various aetiologies, but particularly in Ménière's disease. It is also apparent that tinnitus and hearing loss are far less amenable to treatment with betahistine. In addition to these clinical efficacy studies, laboratory studies on patients with vertigo have also yielded interesting results; a dose-dependent effect of betahistine on the vestibulo-ocular reflex was demonstrated ([@b49-ndt-3-429]) in paroxysmal vertigo patients who had previously responded to betahistine.

Comparative studies with betahstine during the early years of its investigation suggested that it was less effective than trimetazidine ([@b52-ndt-3-429]; [@b63-ndt-3-429]), and flunarizine ([@b33-ndt-3-429]) (though this has been challenged in later studies \[[@b4-ndt-3-429]\]) and at least as effective as cinnarizine ([@b27-ndt-3-429]) and prochlorperazine ([@b1-ndt-3-429]). However, few of these studies are altogether convincing and fewer still have been replicated.

Betahistine continued to be used in many territories on this less than ideal evidence base for many years, although the Food and Drug Administration were unconvinced by the data and withdrew the drug's licence. It remains unlicensed in the US, although widely available elsewhere and anecdotal evidence suggests that patients in the US frequently obtain the drugs overseas.

More robust clinical evidence is available from recent clinical trials and the remainder of this review will focus on these studies, some very recent and others as yet unpublished. These studies are evaluated below and summarized in [Table 1](#t1-ndt-3-429){ref-type="table"}.

Placebo-controlled trials
-------------------------

In a double-blind, parallel group study undertaken at 11 centers in Italy, a total of 144 patients with peripheral vestibular vertigo (including Meniere's disease and paroxyxsmal peripheral vertigo of suspected vascular origin) were randomized to receive either placebo or betahistine 8 mg twice daily for up to 3 months ([@b65-ndt-3-429]). Efficacy was determined by the frequency, severity and duration of vertigo attacks, the GISFaV self-rating scale and Dizziness Handicap Inventory (DHI). After 3 months of treatment the mean frequency of vertigo attacks was reduced from 6.7 per month at baseline to 2.06 per month in Meniere's disease patients and from 6.9 per month to 1.91 per month in PPV patients. The difference between betahistine and placebo was significant from the end of the first month's treatment onwards ([Figure 3](#f3-ndt-3-429){ref-type="fig"} and [Figure 4](#f4-ndt-3-429){ref-type="fig"}). The vertigo intensity score was more frequently improved on betahistine than on placebo, a difference that was significant from day 15 onwards and associated symptoms (tinnitus, aural fullness, nausea, and vomiting was also more frequently improved on betahistine than on placebo. GISFaV scores improved in 70% of betahisitine patients, but in only 30% of the placebo group, moreover, the proportion of patients GISFaV of zero at 3 months was 57% in the betahistine-treated patients compared to 3% in those given placebo. Similarly the six of the seven items in the Dizziness Assessment Rating Scale were improved more by betahistine than by placebo. Betahistine significantly reduced DHI scores significantly more freqently than placebo. The physican's rating of treatment was good or very good in 74% of betahistine-treated patients compared with 27% of placebo-treated patients.

### Comparative studies

Dizziness Handicap Score was used as the primary efficacy variable in a study by Albera and colleagues ([@b4-ndt-3-429]). Seventy-eight patients who were severely handicapped vertigo of peripheral vestibular origin were randomized to receive 8 weeks treatment with either betahistine 16 mg tid or flunarizine 10 mg od. Although DHI score decreased significantly in both groups during treatment, the decrease on betahistine treatment was significantly greater than that on flunarizine (decrease from baseline of 12.4 for betahistine vs 8.8 for flunarizine, p \< 0.01). Vegetative symptoms (of which nausea was the most common) decreased significantly in both groups, without significant difference between the treatments. Tinnitus was the most refractory symptom with no significant reduction by either treatment. Betahistine also appeared to be somewhat quicker in reducing the handicap associated with vertigo. Although there was no significant difference between the treatments in their reduction of vegetative symptoms, it was the physical (rather than functional or emotional) subscores of the DHI that showed the greatest difference between betahistine and flunarizine (5.7 vs 6.0 for betahistine and flunarizine respectivly, p \< 0.01). Moreover, there was a clear relationship between the improvement of DHI scores and the improvement in vegetative symptoms.

An earlier study by Fraysse and colleagues ([@b37-ndt-3-429]) yielded similar results. In this multicenter, double-blind, randomized trial, in which 55 patients received either betahistine 48 mg/day or flunarizine 10 mg/day, betahistine was significantly superior to flunarizine for frequency and duration of vertigo attacks and the presence of vegetative symptoms. The results of these two studies are in contrast to an earlier 2-month double-blind comparison of betahistine 8 mg tid and flunarizine 10 mg od in 117 patients with vestibular vertigo, which found flunarizine to be significantly superior to betahistine. It is not clear to what extent the lower dose of betahistine used in this study might have contributed to the lack of efficacy that was observed.

Two studies have compared betahistine with the fixed combination of cinnarizine and dimenhydrinate. In the first study by [@b68-ndt-3-429], patients with Méniere's disease were entered into a randomized, double-blind, parallel group study lasting 12 weeks. Eighty-two patients were randomized to treatment with betahistine 12 mg tid or cinnarizine plus dimendydrinate. The intensity of vertigo, as measured by the patient on a visual analogue scale was markedly reduced by both treatments from a baseline score of 2.4--0.31 and 0.4 for betahistine and cinnarizine plus dimendydrinate, respectively, there was no statistically significant difference between the two treatments. Tinnitus and vegetative symptoms were also significantly, and approximately equally, reduced by the two treatments.

Betahistine was used as a reference therapy in the study of a new fixed combination of cinnarizine 20 mg plus dimenhydrinate 40 mg in patients with vertigo of peripheral vestibular origin ([@b18-ndt-3-429]). Sixty-one patients were entered into the single center study and were randomized to 4 weeks of treatment with betahistine 12 mg or cinnarizine plus dimenhydrinate. Both betahistine and cinnarizine plus dimenhydrinate reduced mean vertigo scores, although cinnarizine plus dimenhydrinate was significantly more effective than betahistine. Vertigo-associated symptoms were also reduced more effectively by cinnarizine plus dimenhydrinate than by betahistine.

Open studies
------------

The efficacy of betahistine has also been confirmed in open naturalistic studies. An as yet unpublished study by [@b68-ndt-3-429] found symptoms disappeared or improved in 93% (15% and 78% respectively) of 293 patients with Ménière's disease of at least 3 months duration who were treated with betahistine 16 mg tid.

Safety and tolerability
-----------------------

Adverse events appear to be rare during betahistine therapy, mild skin reactions are the most common and epigastric upset is reported occasionally as is headache and nausea (the latter also a symptom of the illness being treated). Although formal safety and tolerability studies have not been undertaken to modern standards the drug has been used for many decades and tens of millions of patients have been exposed without significant safety or tolerability concerns having arisen.

Discussion
==========

Ménière's is a relatively common and debilitating otological condition. Whilst many drug therapies are employed, the great majority hamper vestibular adaptation and, whilst reducing the distressing symptoms of vertigo, may hinder long-term recovery. Betahistine has been a staple of the treatment of Ménière's disease and other disorders that include vertigo as a cardinal symptom. Until recently however, evidence for its efficacy has not been available to modern standards of proof. The past 10 years have seen significant advances, not only in clarifying the efficacy of betahistine, but also in our understanding of its mechanism of action -- a remarkable situation for a drug that has been in routine clinical use for more than 40 years.

Besides vascular action in the inner ear, modulation of the peripheral vestibular sensory cells, and excitatory effect on the neuronalactivity of corticaland subcortical structures, betahistine interacts strongly with the histaminergic system increasing histamine synthesis and release in the tuberomammillary nuclei of the posterior hypothalamus. The action of histamine on the vestibular cells on the affected side may contribute to a rebalancing of neuronalactivity between the two sides; a key mechanism in the vestibular recovery process. Vestibular deficits require a considerable period for compensation to occur and these long-term adaptive mechanisms can be facilitated pharmacologically using histaminergic-like drugs such as betahistine. Animal studies show clearly that betahistine does not interfere with vestibular adaptation in the way that drugs with sedative effects do.

The situation concerning the clinical efficacy of betahistine is now somewhat regularized in that randomized placebo and active controlled clinical trials have confirmed that betahistine is effective in the treatment of Ménière's disease and related conditions. However, compared with modern standards of evidence-based medicine, further trials, randomized, placebo-controlled studies in particular, would be welcome. Nevertheless, the available data from recent well-conducted trials shows that betahistine is more effective than placebo or flunarizine. Comparative studies of betahistine with the fixed combination of cinnarizine and dimenhydrinate are equivocal, whilst there are clear and significant reductions in symptoms with both treatments, their relative efficacy is not clear. More studies are needed, but it is now clear that betahistine is effective in Ménière's disease -- after 40 years of clinical use it would have been surprising if this were not the case -- its freedom from sedative properties that interfere with vestibular adaptation is a major clinical advantage compared with many drugs employed in this field.

Although it remains true that there is still much to learn about betahistine, important advances have been in made in understanding its place in the therapy of Ménière's disease and related illnesses and in elucidating its mechanism of action.

![Mean recovery curves illustrating maximal performance of the cat on the rotating beam. Results are expressed in percent of the preoperative maximal performance (on the ordinates) as a function of the postoperative time in days (on the abscissae). The betahistine groups (50 mg/kg and 100 mg/kg) are shown as solid squares and triangles, respectively, and the control group as open circles. Standard errors of the mean are shown as vertical lines. Note the acceleration of the recovery time under betahistine treatment compared with the controls, and the shortened time required to achieve a full compensation (3 weeks instead of 6 weeks).](ndt-3-429f1){#f1-ndt-3-429}

![Quantification of the histidine decarboxylase (HDC) mRNA labeled surface in the right (hatched columns) and left (solid columns) tuberomammillary (TM) nuclei for the two groups of betahistine-treated cats compared with the control, untreated cats (open columns). Note that HDC mRNA labeled surface is significantly increased in the TM nuclei of betahistine-treated cats. \*\* p \< 0.0001.](ndt-3-429f2){#f2-ndt-3-429}

![Percentage improvement in frequency of vertigo attacks -- Menière's disease. Reproduced with permission from [@b65-ndt-3-429]. Betahistine dihydrochloride in the treatment of peripheral vestibular vertigo. *Eur Arch Otorhinolaryngol*, 260:73--7. Copyright © 2003 Springer.](ndt-3-429f3){#f3-ndt-3-429}

![Percentage improvement in frequency of vertigo attacks -- peripheral paroxysmal vertigo. Reproduced with permission from F[@b65-ndt-3-429]. Betahistine dihydrochloride in the treatment of peripheral vestibular vertigo. *Eur Arch Otorhinolaryngol*, 260:73--7. Copyright © 2003 Springer.](ndt-3-429f4){#f4-ndt-3-429}

###### 

Summary of recent placebo and active control trials of betahistine

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reference          N        Methodology                                              Diagnosis                                                                         Treatment                                                              Duration   
  ------------------ -------- -------------------------------------------------------- --------------------------------------------------------------------------------- ---------------------------------------------------------------------- ---------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  [@b4-ndt-3-429]    \(52\)   Double-blind, randomized, muliticenter                   Recurrent vetibular vertigo                                                       Betahistine Flunarazne                                                 8 weeks    Betahistine significantly more effective then flunarizine on DHI and physical, functional and functional subscores.

  [@b65-ndt-3-429]   144      Double-blind, multi-center, randomized, parallel group   Ménière's 's disease or paroxysmal position vertigo of possible vascular origin   Placebo Betahistine 16 mg tid                                          3 months   Frequency, intensity and duration of attacks significantly reduced compared with placebo.\
                                                                                                                                                                                                                                                           Physician's judgment and patient's opinion of efficacy and acceptability favored betahistine

  [@b68-ndt-3-429]   82       randomized, double-blind                                 Ménière's disease                                                                 Betahistine 12 mg tid cinnarizine, 20 mg + dimenhydrinate, 40 mg tid   12 weeks   Highly significant reduction in vertigo symptoms, no difference between treatments. Significant improvement in hearing function noted for cinnarizine + dimenhydrinate

  [@b18-ndt-3-429]   61       double-blind, comparative, single center                 peripheral vestibular vertigo                                                     Betahistine 12 mg tid cinnarizine 20 mg + dimenhydrinate 40 mg tid     4 weeks    Significantly greater reduction in vertigo score with cinnarizine+ dimenhydrinate than with betahistine
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
